Skip to Main Content

Paper Details

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Gynecol Oncol
88
2018
Paclitaxel, advanced endometrial cancer, advanced/recurrent endometrial cancer, bevacizumab, carboplatin, endometrial cancer, histotype, ixabepilone, mismatch repair protein, paclitaxel, patients, temsirolimus
Author NameAffiliation
Jianjiong GaoKravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Jianjiong GaoKravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Robert A SoslowMemorial Sloan Kettering Cancer Center and Weill Cornell Medical Center
Douglas A LevineLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center
Douglas A LevineLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center
  • 1 - 5

Datasets

Release 1.2